Charles Truillet

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3248935/publications.pdf

Version: 2024-02-01

45 papers	1,733 citations	279701 23 h-index	289141 40 g-index
46 all docs	46 docs citations	46 times ranked	3502 citing authors

#	Article	IF	Citations
1	⁶⁸Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. Journal of Nuclear Medicine, 2017, 58, 81-84.	2.8	166
2	Long-Term in Vivo Clearance of Gadolinium-Based AGuIX Nanoparticles and Their Biocompatibility after Systemic Injection. ACS Nano, 2015, 9, 2477-2488.	7.3	132
3	Development of a stress response therapy targeting aggressive prostate cancer. Science Translational Medicine, 2018, 10, .	5.8	124
4	X-ray-Induced Singlet Oxygen Activation with Nanoscintillator-Coupled Porphyrins. Journal of Physical Chemistry C, 2013, 117, 21583-21589.	1.5	117
5	A Topâ€Down Synthesis Route to Ultrasmall Multifunctional Gdâ€Based Silica Nanoparticles for Theranostic Applications. Chemistry - A European Journal, 2013, 19, 6122-6136.	1.7	115
6	Imaging PD-L1 Expression with ImmunoPET. Bioconjugate Chemistry, 2018, 29, 96-103.	1.8	109
7	Advantages of gadolinium based ultrasmall nanoparticles vs molecular gadolinium chelates for radiotherapy guided by MRI for glioma treatment. Cancer Nanotechnology, 2014, 5, 4.	1.9	93
8	AGuIX^{Â®} from bench to bedsideâ€"Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine. British Journal of Radiology, 2019, 92, 20180365.	1.0	86
9	Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins. ELife, 2018, 7, .	2.8	72
10	Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade. Genes and Development, 2017, 31, 2067-2084.	2.7	57
11	Functionalization of Small Rigid Platforms with Cyclic RGD Peptides for Targeting Tumors Overexpressing Î±_vÎ²₃-Integrins. Bioconjugate Chemistry, 2013, 24, 1584-1597.	1.8	49
12	Caged [¹⁸F]FDG Glycosylamines for Imaging Acidic Tumor Microenvironments Using Positron Emission Tomography. Bioconjugate Chemistry, 2016, 27, 170-178.	1.8	38
13	Impact of blood-brain barrier permeabilization induced by ultrasound associated to microbubbles on the brain delivery and kinetics of cetuximab: An immunoPET study using 89Zr-cetuximab. Journal of Controlled Release, 2020, 328, 304-312.	4.8	38
14	A Preclinical Assessment of ⁸⁹Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with ⁸⁹Zr-C4. Bioconjugate Chemistry, 2018, 29, 3476-3482.	1.8	37
15	Longitudinal positron emission tomography imaging of glial cell activation in a mouse model of mesial temporal lobe epilepsy: Toward identification of optimal treatment windows. Epilepsia, 2018, 59, 1234-1244.	2.6	36
16	⁶⁸Ga-radiolabeled AGuIX nanoparticles as dual-modality imaging agents for PET/MRI-guided radiation therapy. Nanomedicine, 2017, 12, 1561-1574.	1.7	34
17	Bifunctional polypyridyl-Ru(ii) complex grafted onto gadolinium-based nanoparticles for MR-imaging and photodynamic therapy. Dalton Transactions, 2013, 42, 12410.	1.6	32
18	Noninvasive Measurement of mTORC1 Signaling with 89Zr-Transferrin. Clinical Cancer Research, 2017, 23, 3045-3052.	3.2	31

#	Article	IF	Citations
19	Ultrasmall particles for Gdâ€MRI and ⁶⁸Gaâ€PET dual imaging. Contrast Media and Molecular Imaging, 2015, 10, 309-319.	0.4	30
20	Coupling of HPLC with Electrospray Ionization Mass Spectrometry for Studying the Aging of Ultrasmall Multifunctional Gadolinium-Based Silica Nanoparticles. Analytical Chemistry, 2013, 85, 10440-10447.	3.2	28
21	A reactivity-based [¹⁸F]FDG probe for in vivo formaldehyde imaging using positron emission tomography. Chemical Science, 2016, 7, 5503-5507.	3.7	27
22	Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Molecular Cancer Research, 2017, 15, 1221-1229.	1.5	27
23	TSPO-PET and diffusion-weighted MRI for imaging a mouse model of infiltrative human glioma. Neuro-Oncology, 2019, 21, 755-764.	0.6	26
24	Synthesis and Characterization of ⁸⁹Zr-Labeled Ultrasmall Nanoparticles. Molecular Pharmaceutics, 2016, 13, 2596-2601.	2.3	24
25	Development of gadolinium based nanoparticles having an affinity towards melanin. Nanoscale, 2013, 5, 1603.	2.8	23
26	New fluorine-18 pretargeting PET imaging by bioorthogonal chlorosydnoneâ€“cycloalkyne click reaction. Chemical Communications, 2019, 55, 10400-10403.	2.2	22
27	PET imaging of immune checkpoint proteins in oncology. , 2021, 222, 107786.		20
28	Site-Specific Radiofluorination of Biomolecules with 8-[¹⁸F]-Fluorooctanoic Acid Catalyzed by Lipoic Acid Ligase. ACS Chemical Biology, 2016, 11, 1587-1594.	1.6	18
29	Complete inhibition of ABCB1 and ABCG2 at the bloodâ€“brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [¹¹C]erlotinib. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1634-1646.	2.4	17
30	Applying ⁸⁹Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins. Molecular Pharmaceutics, 2016, 13, 683-688.	2.3	12
31	Development of 5N-Bicalutamide, a High-Affinity Reversible Covalent Antiandrogen. ACS Chemical Biology, 2017, 12, 2934-2939.	1.6	11
32	An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers. Molecular Imaging and Biology, 2020, 22, 1553-1561.	1.3	11
33	Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of ⁸⁹Zr-Labeled Anti-PD-L1 Antibody Formats. Journal of Nuclear Medicine, 2022, 63, 1259-1265.	2.8	11
34	Profiling the Surfaceome Identifies Therapeutic Targets for Cells with Hyperactive mTORC1 Signaling. Molecular and Cellular Proteomics, 2020, 19, 294-307.	2.5	8
35	Measuring glucocorticoid receptor expressionin vivowith PET. Oncotarget, 2018, 9, 20399-20408.	0.8	8
36	In vivo evidence of the targeting of cartilaginous tissue by pyridinium functionalized nanoparticles. Chemical Communications, 2013, 49, 3046.	2.2	7

#	Article	IF	Citations
37	Validation of Pharmacological Protocols for Targeted Inhibition of Canalicular MRP2 Activity in Hepatocytes Using [99mTc]mebrofenin Imaging in Rats. Pharmaceutics, 2020, 12, 486.	2.0	7
38	Longitudinal mouse-PET imaging: a reliable method for estimating binding parameters without a reference region or blood sampling. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2589-2601.	3.3	7
39	Quantitative Tissue Pharmacokinetics and EPR Effect of AGuIX Nanoparticles: A Multimodal Imaging Study in an Orthotopic Glioblastoma Rat Model and Healthy Macaque. Advanced Healthcare Materials, 2021, 10, e2100656.	3.9	7
40	A snake toxin as a theranostic agent for the type 2 vasopressin receptor. Theranostics, 2020, 10, 11580-11594.	4.6	5
41	A Novel Radioligand Reveals Tissue Specific Pharmacological Modulation of Glucocorticoid Receptor Expression with Positron Emission Tomography. ACS Chemical Biology, 2020, 15, 1381-1391.	1.6	4
42	The Synthesis and Structural Requirements for Measuring Glucocorticoid Receptor Expression In Vivo with (Â±)-¹¹C-YJH08 PET. Journal of Nuclear Medicine, 2021, 62, 723-731.	2.8	2
43	Imaging-Based Characterization of a Slco2b1(-/-) Mouse Model Using [11C]Erlotinib and [99mTc]Mebrofenin as Probe Substrates. Pharmaceutics, 2021, 13, 918.	2.0	2
44	Pharmacokinetic Imaging Using 99mTc-Mebrofenin to Untangle the Pattern of Hepatocyte Transporter Disruptions Induced by Endotoxemia in Rats. Pharmaceuticals, 2022, 15, 392.	1.7	2
45	Innovative multimodal DOTA/NODA nanoparticles for MRI and PET imaging for tumor detection. EJNMMI Physics, 2014, 1, A80.	1.3	1